Percutaneous Left Atrial Appendage Occlusion Therapy: Evolution and Growing Evidence

Area of Science:

• Cardiology
• Medical Devices
• Interventional Cardiology

Background:

• Atrial fibrillation (AF) is a common arrhythmia increasing stroke risk, often originating from the left atrial appendage (LAA).
• Oral anticoagulation (OAC) is standard for stroke prevention but carries bleeding risks and compliance issues.
• Surgical LAA excision is invasive and limited in application; percutaneous LAA occlusion (LAAO) has emerged as an alternative.

Purpose of the Study:

• To systematically review the development and clinical evidence for percutaneous left atrial appendage occlusion (LAAO) in nonvalvular AF (NVAF).
• To evaluate US FDA and CE-Mark approved LAAO devices and summarize the current status of the therapy.
• To discuss future perspectives, knowledge gaps, and the impact of ongoing clinical trials in LAAO.

Main Methods:

• Systematic literature review focusing on the evolution of LAAO.
• Analysis of clinical evidence supporting LAAO in NVAF patients.
• Evaluation of approved LAAO devices and current therapeutic status.

Main Results:

• LAAO is increasingly performed as an alternative to OAC for stroke prevention in NVAF, particularly in high-bleeding-risk patients.
• Significant progress has been made in LAAO device technology and clinical application over the past two decades.
• Ongoing clinical trials are expected to further define the role and optimize the use of LAAO.

Conclusions:

• Percutaneous LAAO represents a significant advancement in stroke prevention for NVAF patients.
• The therapy is a viable alternative to OAC, especially for patients with contraindications or high bleeding risk.
• Future research and technological advancements will likely expand the utility and effectiveness of LAAO.